Galmed Pharmaceuticals Ltd. (GLMD): Price and Financial Metrics
GET POWR RATINGS... FREE!
GLMD Stock Price Chart Interactive Chart >
GLMD Price/Volume Stats
| Current price | $0.56 | 52-week high | $4.08 |
| Prev. close | $0.50 | 52-week low | $0.50 |
| Day low | $0.50 | Volume | 152,900 |
| Day high | $0.56 | Avg. volume | 111,110 |
| 50-day MA | $1.30 | Dividend yield | N/A |
| 200-day MA | $2.09 | Market Cap | 14.02M |
Galmed Pharmaceuticals Ltd. (GLMD) Company Bio
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company was founded in 2000 and is based in Tel Aviv, Israel.
Latest GLMD News From Around the Web
Below are the latest news stories about Galmed Pharmaceuticals Ltd that investors may wish to consider to help them evaluate GLMD as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayGood morning, trader! |
Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine SaltGalmed Pharmaceuticals Ltd. (NASDAQ-CM: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the United States Patent and Trademark Office (USPTO) granted Galmed new patents related to the use of Aramchol for the treatment of fibrosis and for the treatment for modulating gut microbiota. An additional patent grant protects the low dose composition of Aramchol salt until June 8, 2036. With these latest pat |
Galmed announces positive results of Phase 1 study of Amilo-5MERGalmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today results of a Phase 1 clinical trial of Amilo-5MER in healthy volunteers that demonstrated an excellent safety profile and tolerability. |
Analysts Are Bullish on Top Healthcare Stocks: ImmunoGen (IMGN), TG Therapeutics (TGTX)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ImmunoGen (IMGN – Research Report), TG Therapeutics (TGTX – Research Report) and Galmed Pharmaceuticals (GLMD – Research Report) with bullish sentiments. ImmunoGen (IMGN) In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on ImmunoGen, with a price target of $12.00. The company's shares closed last Tuesday at $6.17. According to TipRanks. |
Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial ResultsGalmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and fibrosis, provides today updated information on the Company's scientific and clinical development programs and reports financial results for the three and nine months ended September 30, 2021. |
GLMD Price Returns
| 1-mo | -63.87% |
| 3-mo | N/A |
| 6-mo | -77.95% |
| 1-year | -78.71% |
| 3-year | -91.36% |
| 5-year | -88.80% |
| YTD | -69.23% |
| 2021 | -41.48% |
| 2020 | -46.19% |
| 2019 | -15.37% |
| 2018 | -25.36% |
| 2017 | 160.68% |
Continue Researching GLMD
Want to do more research on Galmed Pharmaceuticals Ltd's stock and its price? Try the links below:Galmed Pharmaceuticals Ltd (GLMD) Stock Price | Nasdaq
Galmed Pharmaceuticals Ltd (GLMD) Stock Quote, History and News - Yahoo Finance
Galmed Pharmaceuticals Ltd (GLMD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...